Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 14/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.83 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.83 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.83 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.83 |
| ▸ | CCR2 | P41597 | 1/20 | 0.83 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.83 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.83 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.83 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30641657 | 0.98 | CXCR4 (0.81) | CXCR4MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL31616422 | 0.98 | SIGMAR1 (0.82) | CXCR4MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL255099 | 0.96 | SIGMAR1 (0.85) | CXCR4MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL15043649 | 0.96 | SIGMAR1 (0.85) | CXCR4MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL10316935 | 0.96 | SIGMAR1 (0.85) | CXCR4MEN1KMT2ACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL7422770 | 0.95 | SIGMAR1 (0.82) | CXCR4MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL15046526 | 0.95 | CXCR4 (0.75) | CXCR4MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL3999326 | 0.93 | CXCR4 (0.79) | CXCR4MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL3779720 | 0.93 | CXCR4 (0.78) | CXCR4MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL6632216 | 0.91 | SIGMAR1 (0.82) | CXCR4MEN1KMT2ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452845-B2 | Mesoporous organic-inorganic hybrid materials for separating gases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-11-18 | — | — | US | claimed |
| EP-1370563-B1 | MESOPOROUS ORGANIC-INORGANIC HYBRID MATERIALS FOR SEPARATING GASES | CENTRE NAT RECH SCIENT (FR) | 2006-09-06 | — | — | EP | claimed |
| US-20040122250-A1 | Mesoporous organic-inorganic hybrid materials for separating gases | CENTRE NATIONAL DE LA RECHERCHE-SCIENTIFIQUE (FR) | 2004-06-24 | — | — | US | claimed |
| EP-1189609-A4 | CXCR-4 RECEPTOR ANTAGONISTS - THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2002-10-30 | — | — | EP | claimed |
| EP-1189609-A1 | CXCR-4 RECEPTOR ANTAGONISTS - THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-03-27 | — | — | EP | claimed |
| WO-2000066112-A1 | CXCR-4 RECEPTOR ANTAGONISTS - THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-09 | — | — | WO | claimed |
| US-20250257148-A1 | ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents | CROSSLINK THERAPEUTICS INC (US) | 2025-08-14 | — | — | US | disclosed |
| WO-2025054553-A1 | ATP-DEPENDENT AGONISTS OF IMMUNE CELLS FUNCTION AS ANTICANCER AGENTS | CROSSLINK THERAPEUTICS INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| EP-4273142-A1 | PICOLINATE CYCLAM PALLADIUM CHELATES AND USES THEREOF | Université de Bretagne Occidentale (FR) | 2023-11-08 | — | — | EP | disclosed |
| CN-113429428-B | Octahydropyrazinopyrimidine molecular clamp compound, preparation method and application thereof | 北京百灵威科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-113429428-A | Octahydropyrazinopyrimidine molecular clamp compound, preparation method and application thereof | 北京百灵威科技有限公司 | 2021-09-24 | — | — | CN | disclosed |
| US-9233971-B2 | Lipomacrocycles and uses thereof | AGAVE PHARMA, INCORPORATED | 2016-01-12 | — | — | US | disclosed |
| US-9233971-B2 | Lipomacrocycles and uses thereof | AGAVE PHARMA, INCORPORATED | 2016-01-12 | — | — | US | disclosed |
| US-6524372-B1 | Separation and purification of gases; 1,4,8,11-Tetrakis(3-(triethoxysilyl)propyl)-1,4,8,11 -tetraazacyclotetradecane | L′Air Liquide, Societe Anonyme a Directoire et Conseil de Surveillance pour l′Etude et l′Exploitation des Procedes Georges Claude (FR) | 2003-02-25 | — | — | US | disclosed |
| US-6372903-B1 | REACTING POLYAZACYCLOALKANE WITH COMPOUND HAVING FUNCTIONAL SILANE GROUP, CONDENSING PRODUCT WITH SILANOL SITES OF SILICA GEL TO FORM IMMOBILIZED POLYAZACYCLOALKANE | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2002-04-16 | — | — | US | disclosed |
| EP-1051257-B1 | METHOD FOR PREPARING POLYAZACYCLOALKANES GRAFTED ON SILICA GEL AND USE OF GRAFTED COMPOUNDS | AIR LIQUIDE (FR) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001046202-A1 | POLYAZACYCLOALKANES, ORGANOMETALLIC COMPLEXES THAT INCORPORATE THEM AS LIGANDS AND THE USE OF SAID COMPOUNDS IN THE EXTRACTION OF HEAVY METALS | L'AIR LIQUIDE SOCIETE ANONYME A DIRECTOIRE ET CONSEIL DE SURVEILLANCE POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2001-06-28 | — | — | WO | disclosed |
| EP-1051422-A1 | SILICA GEL INCORPORATING POLYAZACYCLOALKANE STRUCTURAL UNITS | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999037656-A1 | SILICA GEL INCORPORATING POLYAZACYCLOALKANE STRUCTURAL UNITS | L'AIR LIQUIDE SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 1999-07-29 | — | — | WO | disclosed |
| WO-1996011189-A1 | POLYAZACYCLOALKANE DERIVATIVES, THEIR METAL COMPLEXES AND PHARMACEUTICAL PRODUCTS INCORPORATING THESE COMPLEXES | L'AIR LIQUIDE SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122250-A1 | Mesoporous organic-inorganic hybrid materials for separating gases | SCO2, IPO9, IPO4 | CXCR4 1677/4885MEN1 1178/4885KMT2A 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.